(Q40090864)

17 September 2017

1 reference

title

Multiple dopamine receptors and behavior (English)

1 reference

17 September 2017

J. N. Joyce

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6136014

12 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6136014

12 August 2023

publication date

1 January 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0149763483900179?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

https://api.elsevier.com/content/article/PII:0149763483900179?httpAccept=text/plain

12 August 2023

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuroscience & Biobehavioral Reviews

12 August 2023

published in

1 reference

17 September 2017

volume

7

1 reference

17 September 2017

issue

2

1 reference

17 September 2017

page(s)

227-256

1 reference

GnRH Interaction with Anterior Pituitary. II. Cyclic AMP as an Intracellular Mediator in the GnRH Activated Gonadotroph1

17 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The Neuroleptic Hypothesis: Study of the Covariation of Extrapyramidal and Therapeutic Drug Effects

12 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clozapine's anti-acetylcholine property modulates its antistereotypic action in the mesolimbic sytem

12 August 2023

6

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system

12 August 2023

7

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

12 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Handwriting changes and response to drugs--a controlled study

12 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Ergot alkaloids as dopamine agonists: comparison in two rodent models

12 August 2023

10

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential reversal by scopolamine and thip of the antistereotypic and cataleptic effects of neuroleptics

12 August 2023

11

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol

12 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stimulatory action of lisuride on dopamine-sensitive adenylate cyclase in the rat striatal homogenate

12 August 2023

13

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists

12 August 2023

14

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Biochemical mechanism of tolerance to neuroleptic drugs; Regional differences in rat brain

12 August 2023

15

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regional sensitivity of primate brain dopaminergic neurons to haloperidol: alterations following chronic treatment

12 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antipsychotic Drug Action in Schizophrenic Patients: Effect on Cortical Dopamine Metabolism After Long-Term Treatment

12 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors in rat frontal cortex: Pharmacological properties in vivo and in vitro

12 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol

12 August 2023

19

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Evidence for an irreversible interaction of bromocryptine with central dopamine receptors

12 August 2023

20

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurones

12 August 2023

21

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Six years of high-level levodopa therapy in severely akinetic parkinsonian patients

12 August 2023

23

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease

12 August 2023

24

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system

12 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Ligand binding to dopamine-receptors: analysis & interpretation

12 August 2023

26

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Blockade of amphetamine-induced locomotor activity and stereotypy in rats by spiroperidol but not by an atypical neuroleptic, thioridazine

12 August 2023

27

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

12 August 2023

28

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Tardive Dyskinesia: Clinical, Biological, and Pharmacological Perspectives

12 August 2023

29

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Compulsive gnawing in rats after implantation of drugs into the ventral thalamus. A contribution to the mechanism of morphine action

12 August 2023

30

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia

12 August 2023

31

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. II. Distribution and characteristics of dopamine adenylate cyclase — Interaction of d-LSD with dopaminergic receptors

12 August 2023

32

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Biochemical processes in schizophrenia: an update

12 August 2023

34

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs

12 August 2023

35

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study

12 August 2023

36

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine/neuroleptic receptors in basal hypothalamus and pituitary

12 August 2023

38

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Relevance of drug-induced extrapyramidal reactions to behavioral changes during neuroleptic treatment. I. Treatment with trifluoperazine singly and in combination with trihexyphenidyl

12 August 2023

39

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Loss of striatal neurons in Parkinson's disease: a cytometric study

12 August 2023

40

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Drug therapy and psychobiological research advances in the psychoses in the past decade

12 August 2023

41

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

d -Amphetamine-Induced Inhibition of Central Dopaminergic Neurons: Mediation by a Striato-Nigral Feedback Pathway

12 August 2023

42

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The precise localization of nigral afferents in the rat as determined by a retrograde tracing technique

12 August 2023

43

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity

12 August 2023

44

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Extrapyramidal side-effects

12 August 2023

45

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clozapine and the Dopamine Hypothesis of Schizophrenia, a Critical Appraisal

12 August 2023

46

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain

12 August 2023

49

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Binding of dopamine to bovine anterior pituitary gland membranes

12 August 2023

51

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Role of ergot derivatives in the treatment of parkinsonism

12 August 2023

52

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Long-term treatment of parkinsonism with bromocriptine

12 August 2023

53

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stereochemical characteristics of dopamine agonists: molecular structure of bromocriptine and structural comparisons with apomorphine

12 August 2023

54

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Does dopamine play a role in schizophrenia?

12 August 2023

56

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dystonic reactions in children caused by metoclopramide

12 August 2023

58

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Psychosis and Other Psychiatric Manifestations of Levodopa Therapy

12 August 2023

59

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist

12 August 2023

60

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Endogenous components of the striatum confer dopamine-sensitivity upon adenylate cyclase activity: The role of endogenous guanyl nucleotides

12 August 2023

61

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antiparkinsonian agents and depot phenothiazine

12 August 2023

62

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase

12 August 2023

63

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Penfluridol: a long acting oral antipsychotic drug

12 August 2023

64

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Pimozide in chronic schizophrenic outpatients

12 August 2023

65

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment

12 August 2023

66

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Adenylyl cyclase from a prolactin producing tumor cell: the effect of phenothiazines

12 August 2023

67

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor topography. Characterization of antagonist requirements of striatal dopamine-sensitive adenylate cyclase using protoberberine alkaloids

12 August 2023

68

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Characterization of a dopamine-sensitive adenylate cyclase in the rat caudate nucleus

12 August 2023

69

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine-sensitive adenylate cyclase from the rat caudate nucleus: regulation by guanyl nucleotides and the interaction of magnesium and magnesium ATP

12 August 2023

70

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Apparent lack of a dopaminergic-cholinergic link in the rat nucleus accumbens septi-tuberculum olfactorium

12 August 2023

73

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Supersensitivity of the cholinergic response to apomorphine in the striatum following denervation or disuse supersensitivity of dopaminergic receptors in the rat

12 August 2023

74

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Two functionally and pharmacologically distinct dopamine receptors in the rat brain

12 August 2023

75

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors: selective agonists and antagonists of functionally distinct types within the feline brain

12 August 2023

76

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data

12 August 2023

77

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Multiple receptors for brain dopamine in behavior regulation: Concept of dopamine-e and dopamine-i receptors

12 August 2023

78

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Topographical analysis of the actions of 2(N,N-dipropyl)amino-5,6-dihydroxytetralin to cause biting behaviour and locomotor hyperactivity from the striatum of the guinea-pig

12 August 2023

79

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A study of drug action on normal and denervated striatal mechanisms

12 August 2023

80

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei

12 August 2023

81

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour

12 August 2023

82

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Extrapyramidal and mesolimbic involvement with the stereotypic activity of D- and L-amphetamine

12 August 2023

83

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The behavioural effects of dopamine applied intracerebrally to areas of the mesolimbic system

12 August 2023

84

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine

12 August 2023

85

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias

12 August 2023

86

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems

12 August 2023

87

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The hypotheses of different dopamine receptor mechanisms

12 August 2023

88

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas

12 August 2023

89

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stereotypic and anticataleptic activities of amphetamine after intracerebral injections

12 August 2023

90

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into the caudate-putamen, globus pallidus and substantia nigra of rat brain

12 August 2023

91

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Investigations into the nature of the peri-oral movements induced by 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin

12 August 2023

92

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Design of agents for stimulation of neostriatal dopaminergic mechanisms

12 August 2023

93

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Non-specific supersensitivity of striatal dopamine receptors after 6-hydroxydopamine lesion of the nigrostriatal pathway

12 August 2023

94

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5'-triphosphate

12 August 2023

95

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor binding: Differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol

12 August 2023

98

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

12 August 2023

99

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat

12 August 2023

100

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-spiroperidol labels dopamine receptors in pituitary and brain

12 August 2023

101

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Radioligand binding studies: evidence for multiple dopamine receptors

12 August 2023

102

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors: subtypes, localization and regulation

12 August 2023

103

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Species variations in dopamine receptor binding

12 August 2023

105

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor binding regulated by guanine nucleotides

12 August 2023

106

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Guanine nucleotides distinguish between two dopamine receptors

12 August 2023

107

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3HSpiroperidol (Spiperone) Binding to a Putative Dopamine Receptor in Sheep and Steer Pituitary and Stalk Median Eminence*

12 August 2023

108

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Molecular pathology of schizophrenia: more than one disease process?

12 August 2023

109

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Monoamine Mechanisms in Chronic Schizophrenia: Post-Mortem Neurochemical Findings

12 August 2023

110

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Guanine nucleotides regulate both dopaminergic agonist and antagonist binding in porcine anterior pituitary

12 August 2023

114

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Sulpiride and Extrapyramidal Syndromes in Chronic Heroin Addiction

12 August 2023

115

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Morphine versus haloperidol catalepsy in the rat: a behavioral analysis of postural support mechanisms

12 August 2023

117

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Destruction of post-synaptic dopamine receptors prevents neuroleptic-induced activation of striatal tyrosine hydroxylase but not dopamine synthesis stimulation

12 August 2023

118

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuroleptic induced extrapyramidal symptoms

12 August 2023

119

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The striatum and substantia nigra: A commentary on their relationships

12 August 2023

120

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The physiology and pharmacology of mammalian basal ganglia

12 August 2023

121

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions.

12 August 2023

122

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. II. Bilateral lesions

12 August 2023

123

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway

12 August 2023

124

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A comparative study of bromocriptine and levodopa in Parkinson's disease

12 August 2023

125

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor changes after long-term haloperidol treatment in rats

12 August 2023

126

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Substituted benzamides as cerebral dopamine antagonists in rodents

12 August 2023

127

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency

12 August 2023

128

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats.

12 August 2023

129

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Is dopamine-sensitive adenylate cyclase involved in regulating the activity of striatal cholinergic neurons?

12 August 2023

131

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

12 August 2023

132

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum

12 August 2023

134

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Substantia nigra dopamine neurons: separate populations project to neostriatum and allocortex

12 August 2023

135

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The structural and biochemical basis of movement disorders in treatment with neuroleptic drugs and in extrapyramidal diseases

12 August 2023

137

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Relationships between selective denervation of dopamine terminal fields in the anterior forebrain and behavioral responses to amphetamine and apomorphine

12 August 2023

139

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Aminergic mechanisms in corpus striatum and amphetamine-induced stereotyped behaviour

12 August 2023

140

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The effect of guanosine nucleotides of [3H]sulpiride binding to rat striatal membranes

12 August 2023

142

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A comparison between some biochemical and behavioural effects produced by neuroleptics

12 August 2023

143

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Catecholamine-Sensitive Guanylate Cyclase from Human Caudate Nucleus

12 August 2023

144

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Actions of neuroleptics on the acetylcholine-induced phospholipid effect in rat neostriatal homogenates

12 August 2023

145

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Characterization of normal and supersensitive dopamine receptors: Effects of ergot drugs and neuropeptides

12 August 2023

147

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders

12 August 2023

149

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Evidence for an exclusive localization of 3H-ADTN binding sites to postsynaptic nerve cells in the striatum of the rat.

12 August 2023

150

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Central monoamine synapses as sites of action for ergot drugs

12 August 2023

151

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuronal links in the CNS: focus on dopaminergic and serotonergic regulation of striatal cholinergic neurons

12 August 2023

152

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum.

12 August 2023

153

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Withdrawal syndromes associated with antipsychotic drugs

12 August 2023

154

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dystonic reaction during maintenance antipsychotic therapy

12 August 2023

155

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study

12 August 2023

156

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine-inhibited adenylate cyclase in female rat adenohypophysis

12 August 2023

157

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential behavioral and biochemical effects of four dopaminergic agonists

12 August 2023

158

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The inhibition of catecholamine biosynthesis by apomorphine

12 August 2023

160

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminephilic properties of ergot alkaloids

12 August 2023

161

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites

12 August 2023

162

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Bromocriptine, Lergotrile: The Antiparkinsonian Efficacy and the Interaction with Monoaminergic Receptors

12 August 2023

163

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Interaction of pergolide with central dopaminergic receptors

12 August 2023

164

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of ergotamine and dihydroergotamine on dopamine-stimulated adenylate cyclase in rat caudate nucleus

12 August 2023

165

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

[(3)H]haloperidol and [(3)H]spiroperidol receptor binding after striatal injection of kainic acid

12 August 2023

166

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Conformational analysis of dopamine by the INDO molecular orbital method

12 August 2023

169

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuroleptic activity in 5-aryltetrahydro-.gamma.-carbolines

12 August 2023

174

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Striatal control of locomotion, intentional actions and of integrating and perceptive activity

12 August 2023

175

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-Clozapine binding to rat brain membranes

12 August 2023

176

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

12 August 2023

179

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Modulation by endogenous dopamine of the release of acetylcholine in the caudate nucleus of the rabbit.

12 August 2023

180

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors

12 August 2023

183

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clinical use of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs

12 August 2023

185

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor blocking activity of sulpiride in the central nervous system

12 August 2023

186

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics

12 August 2023

187

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A prodrug of ADTN: Selectivity of dopaminergic action and brain levels of ADTN

12 August 2023

189

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

2-Amino-6,7-dihydroxytetrahydronaphthalene and the receptor-site preferred conformation of dopamine—a commentary

12 August 2023

190

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

12 August 2023

191

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence

12 August 2023

192

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The effects of standard neuroleptic compounds on the binding of 3H-spiroperidol in the striatum and mesolimbic system of the rat in vitro

12 August 2023

193

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol

12 August 2023

194

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

(+)-Isobutaclamol: a crystallographic, pharmacological, and biochemical study

12 August 2023

195

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of neuroleptics on 3H-haloperidol and 3H-CIS (Z)-flupenthixol binding and on adenylate cyclase activity in vitro

12 August 2023

198

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine Receptors in the Brain

12 August 2023

199

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Catecholamine-sensitive adenylate cyclases in nervous tissues

12 August 2023

200

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine-sensitive adenylate cyclase of the caudate nucleus of rats treated with morphine or haloperidol

12 August 2023

203

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain

12 August 2023

204

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Is the mesocortical dopaminergic system involved in Parkinson disease?

12 August 2023

209

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Mental symptoms in Parkinsonian patients treated with L-dopa.

12 August 2023

210

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stereoselective actions of substituted benzamide drugs on cerebral dopamine mechanisms

12 August 2023

211

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Injections of dopaminergic, cholinergic, serotoninergic and GABAergic drugs into the nucleus accumbens: effects on locomotor activity in the rat

12 August 2023

213

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioral effects of unilateral dopamine injection into dorsal or ventral striatum

12 August 2023

214

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Ultrastructure of acetylcholinesterase synthesizing neurons in the neostriatum

12 August 2023

215

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

Q64864173

216

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Extrapyramidal side-effects of metoclopramide

12 August 2023

217

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Multiple receptors for dopamine

12 August 2023

220

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine

12 August 2023

221

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study

12 August 2023

223

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats

12 August 2023

224

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum

12 August 2023

225

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs

12 August 2023

226

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A pharmacologic analysis of Huntington's chorea

12 August 2023

227

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Drug Therapy of Tardive Dyskinesia

12 August 2023

232

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor blockade by imidoline and its proposed active conformation

12 August 2023

234

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Evidence for in vivo binding of apomorphine and bromocriptine to receptor sites not labelled by 3H-spiperone

12 August 2023

235

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regional blockade by neuroleptic drugs ofin vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies

12 August 2023

236

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

Molecular Pharmacology

238

12

639

Krueger

1976

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The pituitary dopamine receptor

12 August 2023

240

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Specific effect of haloperidol on dopamine turnover in the frontal cortex

12 August 2023

241

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs

12 August 2023

242

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Is the low incidence of extrapyramidal side-effects of antipsychotics associated with antimuscarinic properties?

12 August 2023

243

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Tardive dyskinesia associated with metoclopramide

12 August 2023

245

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Receptor basis for dopaminergic supersensitivity in Parkinson's disease

12 August 2023

246

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Abnormal neuroleptic/dopamine receptors in schizophrenia

12 August 2023

247

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Bromocriptine in parkinsonism. A long-term study

12 August 2023

248

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Kainate lesion dissociates striatal dopamine receptor radioligand binding sites

12 August 2023

249

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential effects of typical and atypical neuroleptics on alpha-noradrenergic and dopaminergic postsynaptic receptors

12 August 2023

250

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics

12 August 2023

251

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy

12 August 2023

252

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Unitary dopaminergic receptor composed of cooperatively linked agonist and antagonist sub-unit binding sites

12 August 2023

254

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential distribution of opiate and neuroleptic receptors and dopamine-sensitive adenylate cyclase in rat brain

12 August 2023

255

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Serotonergic component of neuroleptic receptors

12 August 2023

256

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Treatment of parkinson's disease with bromocriptine

12 August 2023

258

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Changes in the Sensitivity of Dopamine Receptors in the Nucleus Accumbens and in the Striatum Induced by Chronic Ethanol Administration

12 August 2023

260

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

[3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides

12 August 2023

261

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

Q64863799

262

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Anatomy of the dopaminergic neuron systems in the rat brain

12 August 2023

263

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats

12 August 2023

264

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions

12 August 2023

265

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action

12 August 2023

266

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency

12 August 2023

267

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine

12 August 2023

269

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs

12 August 2023

270

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminergic abnormalities in postmortem schizophrenic brain

12 August 2023

272

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-Spiperone binding in normal and schizophrenic post-mortem human brain

12 August 2023

273

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?

12 August 2023

274

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminergic component of [3H]spiroperidol binding in the rat anterior cerebral cortex

12 August 2023

275

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism

12 August 2023

277

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Modification of levodopa effect by systemic decarboxylase inhibition

12 August 2023

278

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The pathophysiology of extrapyramidal side-effects of neuroleptic drugs

12 August 2023

279

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

12 August 2023

281

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Success and problems of long-term levodopa therapy in Parkinson's disease

12 August 2023

282

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Kainic Acid Lesions of the Striatum Dissociate Amphetamine and Apomorphine Stereotypy: Similarities to Huntingdon's Chorea

12 August 2023

283

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Comparative effects of classical and atypical antipsychotic drugs in combination with a non-amphetamine stimulant on rat brain dopamine metabolism

12 August 2023

285

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of dopamine on activation of rat striatal adenylate cyclase by free Mg2+ and guanyl nucleotides

12 August 2023

286

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clinical evidence for multiple dopamine receptors in man

12 August 2023

287

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of morphine, β-endorphin and leu-enkephalin on 3H-spiroperidol binding to bovine pituitary membranes

12 August 2023

288

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with effects on rat prolactin secretion

12 August 2023

289

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Comparison of the dopaminergic effects of apomorphine and (−)-N-n-propylnorapomorphine

12 August 2023

290

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The dopamine receptor in the intermediate lobe of the rat pituitary gland is negatively coupled to adenylate cyclase

12 August 2023

291

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels

12 August 2023

292

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

12 August 2023

293

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Chemical lesion and drug induced supersensitivity and subsensitivity of caudate dopamine receptors

12 August 2023

295

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

From motivation to action: functional interface between the limbic system and the motor system.

12 August 2023

296

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes

12 August 2023

297

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Central catecholamine neuron systems: anatomy and physiology of the dopamine systems

12 August 2023

298

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The dopamine of the rat mammotroph in cell culture as a model for drug action

12 August 2023

299

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of ADTN and various other 2-aminotetralin derivatives on the efflux of 3H-dopamine from rat striatal slices.

12 August 2023

300

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Brain neurotransmitter receptors after long-term haloperidol: Dopamine, acetylcholine, serotonin, α-noradrenergic and naloxone receptors

12 August 2023

301

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminergic supersensitivity after neuroleptics: Time-course and specificity

12 August 2023

302

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Prolactin releasing effect of sulpiride isomers in rats and man

12 August 2023

303

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dompamine receptors in the rat frontal cortex: an autoradiographic study

12 August 2023

304

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Direct evidence for presynaptic and postsynaptic dopamine receptors in brain

12 August 2023

305

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine and Schizophrenia: A Reappraisal in the Light of Clinical Studies with Clozapine

12 August 2023

306

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine

12 August 2023

307

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Cyclic nucleotides and nervous system function

12 August 2023

308

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors in subcellular fractions from bovine caudate: enrichment of [3H]spiperone binding in a postsynaptic membrane fraction

12 August 2023

309

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of lesions in the dorsal or ventral striatum on locomotor activity and on locomotor effects of amphetamine

12 August 2023

311

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Aporphines. 21. Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines

12 August 2023

312

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

An experimental study of the ventral striatum of the golden hamster. I. Neuronal connections of the nucleus accumbens

12 August 2023

313

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

An experimental study of the ventral striatum of the golden hamster. II. Neuronal connections of the olfactory tubercle

12 August 2023

314

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Minireview A systematic study of the pharmacological activities of dopamine antagonists

12 August 2023

315

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurotransmitter receptors-biochemistry and alterations in nueropsychiatric disorders

12 August 2023

317

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioral and biochemical studies of the scopolamine-induced reversal of neuroleptic activity

12 August 2023

318

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Functional development of dopamine receptors in the rat forebrain

12 August 2023

319

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurotransmitter receptors in brain in schizophrenia

12 August 2023

320

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Increased dopamine-receptor sensitivity in schizophrenia

12 August 2023

321

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of bromocriptine on adenylate cyclase and phosphodiesterase activities of rat striatum

12 August 2023

322

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A theoretical conformational study of substituted O-anisamides as models of a class of dopamine antagonists

12 August 2023

323

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Treatment of Parkinsonism With N-n-Propyl Norapomorphine and Levodopa (With or Without Carbidopa)

12 August 2023

324

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopaminergic potency of apomorphine homologues in mice with unilateral lesions of the caudate nucleus

12 August 2023

326

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-Spiroperidol binding to two receptor sites in both the corpus striatum and frontal cortex of rat brain

12 August 2023

327

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain

12 August 2023

328

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

12 August 2023

329

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol

12 August 2023

330

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Further investigations on the effects of ergometrine and other ergot derivatives following injection into the nucleus accumbens of the rat

12 August 2023

332

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Anaesthesia for the geriatric patient

12 August 2023

333

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine

12 August 2023

337

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antagonism by sulpiride of three apomorphine-induced effects in rodents

12 August 2023

338

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Bromocriptin and methylergometrine : Pharmacological approach of the mechanism of their central effects

12 August 2023

339

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Turning behaviour in animals

12 August 2023

340

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The rotating rodent: A two component system?

12 August 2023

341

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regional study of 3H-spiperone binding and the dopamine-sensitive adenylate cyclase in rat brain

12 August 2023

342

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline

12 August 2023

343

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

On the mechanism of desensitization at cholinergic receptors

12 August 2023

344

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Metabolite involvement in bromocriptine-induced circling behaviour in rodents

12 August 2023

345

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurotransmitter receptor alterations in Parkinson's disease

12 August 2023

346

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The localization of receptor binding sites in the substantia nigra and striatum of the rat

12 August 2023

347

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antipsychotics block muscarinic acetylcholine receptor-mediated cyclic GMP formation in cultured mouse neuroblastoma cells

12 August 2023

348

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal

12 August 2023

349

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Recent advances in research on Parkinsonism

12 August 2023

350

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa

12 August 2023

352

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Brain dopamine turnover and the relief of parkinsonism

12 August 2023

353

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.

12 August 2023

355

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Denervation supersensitivity in the mesolimbic system: involvement of dopamine-stimulated adenylate cyclase

12 August 2023

356

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Nucleotide requirement of dopamine sensitive adenylate cyclase in synaptosomal membranes from the striatum of rat brain

12 August 2023

357

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Specificity of the dopamine sensitive adenylate cyclase for antipsychotic antagonists

12 August 2023

358

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Comparative study of the dopamine-sensitive adenylate cyclase in the striatum and hypothalamus of rat brain

12 August 2023

359

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors

12 August 2023

360

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors and dopamine-sensitive adenylate cyclase in canine caudate nucleus. Characterization and solubilization

12 August 2023

361

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Reconstitution of dopamine-sensitive adenylate cyclase from dissociated components in canine caudate nucleus

12 August 2023

362

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Adenosine 3′,5′-cyclic monophosphate as a possible mediator of rotational behaviour induced by dopaminergic receptor stimulation in rats lesioned unilaterally in the substantia nigra

12 August 2023

363

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects

12 August 2023

364

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity

12 August 2023

365

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics

12 August 2023

366

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of ergots on adenylate cyclase activity in the corpus striatum and pituitary

12 August 2023

367

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Striatal lesions with kainic acid: neurochemical characteristics

12 August 2023

368

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum

12 August 2023

369

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Anti-schizophrenic drugs—Membrane receptor sites of action

12 August 2023

370

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

Brain dopamine receptors

371

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antipsychotic drug doses and neuroleptic/dopamine receptors

12 August 2023

373

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients

12 August 2023

374

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regulation of striatal acetylcholine concentration by D2-dopamine receptors

12 August 2023

375

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Rotation produced by administration of dopamine and related substances directly into the supersensitive caudate nucleus

12 August 2023

376

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison

12 August 2023

378

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Guanine nucleotides regulate anterior pituitary dopamine receptors

12 August 2023

379

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor binding in bovine intermediate lobe pituitary membranes

12 August 2023

380

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Animal models of parkinsonism

12 August 2023

381

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile

12 August 2023

382

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Clozapine in tardive dyskinesia

12 August 2023

384

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptors, neuroleptics, and schizophrenia

12 August 2023

385

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Multiple Neurotransmitter Receptors

12 August 2023

386

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

12 August 2023

387

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Three classes of dopamine receptor (D-2, D-3, D-4) identified by binding studies with 3H-apomorphine and 3H-domperidone

12 August 2023

388

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system

12 August 2023

389

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

390

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Interaction of dopaminergic ergot derivatives with cyclic nucleotide system

12 August 2023

391

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue

12 August 2023

392

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Beta-adrenergic receptor-linked adenylate cyclase in rat posterior pituitary

12 August 2023

395

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

An anatomy of schizophrenia?

12 August 2023

396

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum

12 August 2023

397

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine-receptor activity

12 August 2023

398

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

A note on the connections and development of the nucleus accumbens

12 August 2023

399

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Piribedil, a dopamine agonist, in Parkinson's disease

12 August 2023

400

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias

12 August 2023

402

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Topographical distribution of dopaminergic innervation and dopaminergic receptors of the anterior cerebral cortex of the rat.

12 August 2023

403

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-Apomorphine interactions with dopamine receptors in calf brain

12 August 2023

404

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

3H-spiroperidol binding and dopamine-stimulated adenylate cyclase: Evidence for multiple classes of receptors in primate brain regions

12 August 2023

405

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Cation regulation differentiates specific binding of [3 H]sulpiride and [3 H]spiperone to rat striatal preparations

12 August 2023

406

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

High affinity dopamine receptors (D3) in rat brain

12 August 2023

407

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Selective labelling of different dopamine receptors by a new agonist 3H-ligand: 3H-N-propylnorapomorphine

12 August 2023

409

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Subcellular localization of dopamine-sensitive adenylate cyclase and dopamine receptor binding activities

12 August 2023

410

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects of bromocriptine on central dopaminergic receptors

12 August 2023

412

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Ergot Alkaloids and Cyclic Nucleotides in the CNS

12 August 2023

413

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Two dopamine receptors: Supportive evidence with the rat rotational model

12 August 2023

414

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

12 August 2023

416

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine receptor mechanisms: behavioral and electrophysiological studies

12 August 2023

417

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effects on striatal and mesolimbic dopamine systems of a new potential antipsychotic drug -mezilamine- with weak cataleptogenic properties

12 August 2023

418

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects

12 August 2023

419

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Behavioral correlates of dopaminergic function in the nucleus accumbens

12 August 2023

422

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Neurochemical and Neuropharmacological Investigations with Four Ergot Derivatives: Bromocriptine, Dihydroergotoxine, CF 25-397 and CM 29-712

12 August 2023

423

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain

12 August 2023

424

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The distribution and origin of glutamate decar☐ylase and choline acetyltransferase in ventral pallidum and other basal forebrain regions

12 August 2023

425

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs

12 August 2023

426

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Dopamine-sensitive adenylate cyclase in homogenates of rat nucleus accumbens: Structure-activity studies and effects of agonists and antagonists

12 August 2023

427

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

extrapyramidal symptoms

428

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Ligand specificity of state transitions in the cholinergic receptor: behavior of agonists and antagonists

12 August 2023

430

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of kainic acid on striatal dopamine receptors

12 August 2023

431

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs

12 August 2023

432

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Selective storage in vivo of 5,6-ADTN in dopamine-rich areas of the rat brain

12 August 2023

433

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs

12 August 2023

434

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory turbercle of the rat

12 August 2023

435

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Monoamines and monoamine metabolites in brains from demented schizophrenics

12 August 2023

436

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Activation of adenylate cyclase in rat striatum by an ergoline dopamine agonist, pergolide

12 August 2023

437

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Further evidence for the stimulation of rat brain dopamine receptors by ergometrine

12 August 2023

438

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Overview of present day treatment of Parkinson's disease.

12 August 2023

439

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Muscarinic cholinergic receptor binding: Influence of pimozide and chlorpromazine metabolites

12 August 2023

440

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The acute effects of sulpiride on the central dopamine turnover in rats: a quantitative histochemical study

12 August 2023

441

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

Effect of guanine nucleotides on striatal dopamine receptors

12 August 2023

442

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The regulation of striatal tyrosine hydroxylase. Effects of gamma hydroxybutric acid and healperidol

12 August 2023

444

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

The regulation of the kinetic state of striatal tyrosine hydroxylase and the role of postsynaptic dopamine receptors

12 August 2023

445

1 reference

https://api.crossref.org/works/10.1016/0149-7634(83)90017-9

12 August 2023

Identifiers

1 reference

17 September 2017

1 reference